Body Vision Medical, a leader in AI-powered intraoperative imaging, proudly announces a transformative upgrade to its LungVision platform: universal access to AI Tomo imaging.

This achievement enables AI Tomo to be used with nearly any fluoroscopic C-arm model, marking another significant milestone in the company’s mission to improve early and accurate lung cancer diagnosis worldwide.

AI Tomo is Body Vision’s proprietary tomosynthesis-based imaging technology that reconstructs 3D views from widely available 2D imaging systems during bronchoscopy procedures. This innovation eliminates the need for costly 3D fluoroscopy systems. With this advancement, all LungVision users can now visualize even small lesions in real time during both manual and robotic assisted procedures – enhancing precision in every case.

“LungVision technology helps minimize CT-to-body divergence for interventionalists using standard 2D fluoro imaging systems during bronchoscopy procedures,” said Matt Baker, CEO at Body Vision Medical. “Universal AI Tomo gives physicians around the world the technology to maximize their confidence and yields – regardless of the 2D C-arm in use – while significantly reducing radiation exposure for both patients and staff compared to traditional 3D systems.”